Eli Lilly and Company (LLY)
Eli Lilly Warns Tirzepatide-B12 Mix in Compounded Drugs May Pose Safety Risks
Eli Lilly (LLY) has raised new safety concerns around compounded versions of its weight-loss medicine Zepbound, warning that the drug's active ingredient, tirze
Eli Lilly: The Weight-Loss Craze Isn't Over
Eli Lilly is rated a strong buy with a $1,623 price target, driven by multiple near- and long-term catalysts. Orforglipron's Q2 launch and Medicare/Medicaid eligibility will expand LLY's addressable market and offset anticipated price erosion. Retatrutide's potential 2027 approval offers another growth leg, with superior efficacy targeting the most severe obesity cases.
Eli Lilly (LLY) Laps the Stock Market: Here's Why
In the closing of the recent trading day, Eli Lilly (LLY) stood at $1, denoting a +1.82% move from the preceding trading day.
Eli Lilly says some Medicare plans may exceed $50 cap for weight-loss drugs
Eli Lilly said on Monday a small number of basic Medicare drug plans may not follow the $50 per month cap on out-of-pocket costs for its weight-loss drugs, under the Medicare agency's weight-loss drug coverage model.
Lilly (LLY) Down 3.7% Since Last Earnings Report: Can It Rebound?
Lilly (LLY) reported earnings 30 days ago. What's next for the stock?
What Are The Biggest Risks To Eli Lilly Stock?
Eli Lilly stock (LLY) is currently trading near $1,000, reflecting a decline of over 11% from its 52-week high as investors recalibrate expectations against emerging headwinds.
Lilly Stock Down 5% in a Month: Should You Buy Now or Steer Clear?
LLY's shares fall 5% in a month amid pricing fears and obesity-drug rivalry, but booming Mounjaro and Zepbound sales and a deep pipeline keep growth hopes alive.
Eli Lilly launches program to help boost employer coverage of obesity drugs in U.S.
Eli Lilly launched a new program designed to help more employers cover obesity drugs in the U.S., targeting a major barrier to access for patients. The "Employer Connect" platform gives employers more flexibility in how they cover obesity treatments, aiming to broaden employee access to the drugs at low out-of-pocket costs, while also keeping costs within budgets.
Forget AI. This Biotech Stock's Taking Off Right Now
The market seems to be falling heavily out of love with the AI stocks, and for good reason: CapEx is rising at a staggering rate, especially among the Mag Seven AI darlings, all while the question marks surrounding ROIs get bigger.
Here's Why Eli Lilly (LLY) is a Strong Momentum Stock
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Eli Lilly and Company (LLY) is Attracting Investor Attention: Here is What You Should Know
Lilly (LLY) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Eli Lilly and Company (LLY) Presents at TD Cowen 46th Annual Health Care Conference Transcript
Eli Lilly and Company (LLY) Presents at TD Cowen 46th Annual Health Care Conference Transcript
